James Griffin

Sep 30, 2024 | dx.doi.org | James Griffin |James S Nowick |K. Ashley

The peptide antibiotic teixobactin achieves its remarkable activity through the unique pattern of d-l-l-d-d-l-l stereochemistry in amino acid residues 1–7. (1−3) Teixobactin comprises a macrolactone ring (residues 8–11) and a linear tail (residues 1–7); the ring binds the pyrophosphate anion of lipid II and related bacterial cell wall precursor molecules, and the tail forms an amphiphilic β-strand that induces β-sheet assembly (Figure 1).

Sep 25, 2024 | pubs.acs.org | James Griffin |Michael J. Ferracane |Adam G Kreutzer |Jeramiah Small

This publication is Open Access under the license indicated. Learn MoreAddition/CorrectionSeptember 25, 2024*The Journal of Organic ChemistryCite this: J. Org. Chem. 2024, XXXX, XXXClick to copy citationCitation copied!correction. This publication is licensed under CC-BY-NC-ND 4.0 . You are free to share (copy and redistribute) this article in any medium or format within the parameters below:Creative Commons (CC): This is a Creative Commons license.

Sep 25, 2024 | dx.doi.org | James Griffin |Michael J. Ferracane |Adam G Kreutzer |Jeramiah Small

This publication is Open Access under the license indicated. Learn MoreAddition/CorrectionSeptember 25, 2024*The Journal of Organic ChemistryCite this: J. Org. Chem. 2024, XXXX, XXXClick to copy citationCitation copied!correction. This publication is licensed under CC-BY-NC-ND 4.0 . You are free to share (copy and redistribute) this article in any medium or format within the parameters below:Creative Commons (CC): This is a Creative Commons license.

Mar 22, 2023 | mdpi.com | James Griffin |Yan Wu |Qingxin Mu |Xinyan Li

Open AccessArticlebyJames Griffin 1,†, Yan Wu 2,†,‡, Qingxin Mu 1, Xinyan Li 1,3 and Rodney J. Y. Ho 1,* 1Departments of Pharmaceutics, University of Washington, Seattle, WA 98195, USA2Departments of Bioengineering, University of Washington, Seattle, WA 98195, USA3School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China*Author to whom correspondence should be addressed. †These authors contributed equally to this work.